In response to the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee recommendations in May 2020, BMS, IMS, EMAS, RCOG and AMS have produced a joint statement on menopausal hormone therapy (MHT) and breast cancer risk.
In response to the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee recommendations in May 2020, BMS, IMS, EMAS, RCOG and AMS have produced a joint statement on menopausal hormone therapy (MHT) and breast cancer risk.
Install this application on your home screen for quick and easy access when you’re on the go.
Just tap then “Add to Home Screen”
